Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma.

Autor: Sanegre S; Cancer CIBER (CIBERONC), Madrid, Spain.; Department of Pathology, School of Medical, University of Valencia-INCLIVA, Valencia, Spain., Eritja N; Cancer CIBER (CIBERONC), Madrid, Spain.; Institut de Recerca Biomèdica de LLeida (IRBLLEIDA), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Department of Pathology, Hospital U Arnau de Vilanova and Hospital U de Bellvitge, University of Lleida - University of Barcelona, Barcelona, Spain., de Andrea C; Cancer CIBER (CIBERONC), Madrid, Spain.; Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain., Diaz-Martin J; Cancer CIBER (CIBERONC), Madrid, Spain.; Institute of Biomedicine of Sevilla, Virgen del Rocio University Hospital/CSIC/University of Sevilla/CIBERONC, Seville, Spain., Diaz-Lagares Á; Cancer CIBER (CIBERONC), Madrid, Spain.; Cancer Epigenomics, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), Santiago de Compostela, Spain., Jácome MA; Department of Mathematics, MODES Group, CITIC, Faculty of Science, Universidade da Coruña, A Coruña, Spain., Salguero-Aranda C; Cancer CIBER (CIBERONC), Madrid, Spain.; Institute of Biomedicine of Sevilla, Virgen del Rocio University Hospital/CSIC/University of Sevilla/CIBERONC, Seville, Spain., García Ros D; Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain., Davidson B; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway., Lopez R; Cancer CIBER (CIBERONC), Madrid, Spain.; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), Santiago de Compostela, Spain.; Roche-Chus Joint Unit, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain., Melero I; Cancer CIBER (CIBERONC), Madrid, Spain.; Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain., Navarro S; Cancer CIBER (CIBERONC), Madrid, Spain.; Department of Pathology, School of Medical, University of Valencia-INCLIVA, Valencia, Spain., Ramon Y Cajal S; Cancer CIBER (CIBERONC), Madrid, Spain.; Department of Pathology, Vall d'Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain., de Alava E; Cancer CIBER (CIBERONC), Madrid, Spain.; Institute of Biomedicine of Sevilla, Virgen del Rocio University Hospital/CSIC/University of Sevilla/CIBERONC, Seville, Spain., Matias-Guiu X; Cancer CIBER (CIBERONC), Madrid, Spain.; Institut de Recerca Biomèdica de LLeida (IRBLLEIDA), Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Department of Pathology, Hospital U Arnau de Vilanova and Hospital U de Bellvitge, University of Lleida - University of Barcelona, Barcelona, Spain., Noguera R; Cancer CIBER (CIBERONC), Madrid, Spain.; Department of Pathology, School of Medical, University of Valencia-INCLIVA, Valencia, Spain.

Publikováno v: Frontiers in cell and developmental biology [Front Cell Dev Biol] 2021 Jun 03; Vol. 9, pp. 670185. Date of Electronic Publication: 2021 Jun 03 (Print Publication: 2021).